Business Wire

OceanBase Records Over 100% Increase in Number of Customers

13.1.2022 09:59:00 EET | Business Wire | Press release

Share

OceanBase,an enterprise-level distributed relational database provider, announced during this year’s Distributed Database Developer Conference that its database products have been adopted by over 400 customers, which equals to a year-on-year increase of over 100% from 2020 to 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112006074/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yang Bing, CEO of OceanBase, speaking during the Distributed Database Developer Conference on January 6, 2022. (Photo: Business Wire)

OceanBase, an Ant Group company, has seen its business expanding rapidly during the past year. So far, a quarter of the top 200 financial institutions in China have chosen OceanBase as a preferred technology provider to upgrade their core IT systems. OceanBase is also serving customers from non-financial service industries such as energy, telecommunication, and transportation. Customers from these sectors contribute to about 35 percent of OceanBase's total revenue.

Meanwhile, OceanBase is exploring the Small and Medium Enterprises (SMEs) market, which now accounts for near 70 percent of its customer base. Regional banks, insurers, security brokers, and wealth management companies have also been partnering with OceanBase and see it as one of the leading database technology providers.

"With its 'product-driven growth' business model, OceanBase aims to make database system management and operation easier and more seamless, " said Yang Bing, CEO of OceanBase. "We look forward to working with partners, customers, developers, and other industry participants to accelerate the development of database technology with continuous technology and product innovations."

"The distributed database is able to handle computing tasks across different nodes, bringing great advantages to dealing with large throughput and group computing," said Michael “Monty” Widenius, founder at MariaDB Foundation and the main author of the original version of the open-source MySQL in the conference. As for open-sourced database products like MariaDB and OceanBase, he commented, “Products and communities will maintain their vitality when they attract tens of millions of users while building healthy businesses."

The rapid development of the internet industry is accelerating the technology innovations of distributed databases that naturally have the ability to expand on a large scale. According to a recent report released by market intelligence provider Gartner, with advanced features including high availability, high scalability, multimodal implementation, supports of hybrid workloads and high compatibility, native distributed databases such as OceanBase are leading the trend of development in database technology, and the CAGR of the global market reaches 16.9 percent.

This year’s Distributed Database Developer Conference was co-hosted by CSDN, Mulan Open-source Community, Open Source China, and OceanBase on January 6. Other speakers participating in the conference included Bruce Momjian, co-founder and core team member of the PostgreSQL Global Development Group, Li Haixiang, the chief architect of Tencent's distributed database TDSQL, and Liu Song, VP of PingCAP.

About OceanBase

Launched in 2010, OceanBase is an enterprise-level distributed relational database developed by Ant Group. OceanBase’s benefits over alternative solutions include strong data consistency, high availability, high performance, low cost, online scalability, and high compatibility with SQL standards and other mainstream relational databases. Its performance has been proven in many Alipay large-scale business scenarios, as well as at the annual 11.11 Global Shopping Festival. In May 2020, OceanBase set the world record for online transaction processing performance, with 707 million transactions per minute in a TPC-C benchmark test. OceanBase was officially registered as a separate company in June 2020.

To learn more, please visit: https://www.oceanbase.com/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquires
Vick Li Wei
OceanBase
Vick.lw@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye